Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT00542451 trial: what clinicians have said so far
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
- NCT00542451 ↗
- Completed
- Dana-Farber Cancer Institute
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on NCT00542451 (paclitaxel plus trastuzumab in node-negative HER2-positive breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT00542451 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 49 posts on X, typically up to 216 once built | |
| 37 YouTube videos, typically up to 163 once built | |
| 21 podcast episodes, typically up to 92 once built | |
| 4 videos on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Breast Cancer; Carcinoma of the Breast
- Interventions
- Paclitaxel; Trastuzumab
- Arms
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer · Experimental
- Enrollment
- 406
- Primary outcomes
- 3-year Disease Free Survival (DFS) Rate
- Sponsor
- Dana-Farber Cancer Institute with Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Genentech, Inc.
- Start
- Oct 2007
- Primary completion
- Apr 21, 2014
- Results posted
- Yes
- Registry record
- NCT00542451 · updated Jun 26, 2024
Publications
linked from the registry- Tolaney SM, Tarantino P, Graham N, Tayob N, Pare L, Villacampa G, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo JGT, Weiss J, Wagle N, Partridge AH, Waks AG, Hudis CA, Krop IE, Burstein HJ, Prat A, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 Mar;24(3):273-285. doi: 10.1016/S1470-2045(23)00051-7. PubMed 36858723
- Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2. PubMed 30939096
- Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial. Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047. PubMed 30753274
- Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. PubMed 25564897